1. Show article details.

    Meridian Bioscience: Q3 Earnings Insights

    Benzinga – 8:30 AM ET 08/05/2022

      Meridian Bioscience reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Meridian Bioscience reported in-line EPS of $0.16 versus an estimate of $0.16. Revenue was up $4.26 million from the same period last year.

  2. Show article details.

    BRIEF-Meridian Bioscience Inc Reports Q3 Net Loss Per Basic Common Share Of $0.17

    Reuters – 8:22 AM ET 08/05/2022

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS. * Q3 REVENUE ROSE 7 PERCENT TO $67.8 MILLION. * AT JUNE 30, 2022, CASH AND CASH EQUIVALENTS WERE $83.5 MILLION. * QTRLY NET LOSS PER BASIC COMMON SHARE $0.17 Source text for Eikon: Further company coverage:

  3. Show article details.

    MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

    PR Newswire – 8:00 AM ET 08/05/2022

    CINCINNATI, Aug. 5, 2022 Meridian Bioscience, Inc. (VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights: Third Quarter Fiscal 2022 ResultsConsolidated net revenues for the third quarter of fiscal 2022 were $67.8 million, up 7% from $63.5 million in last year's third quarter.

  4. Show article details.

    Earnings Scheduled For August 5, 2022

    Benzinga – 4:49 AM ET 08/05/2022

      ** Reservoir Media is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. ** OFS Capital is estimated to report earnings for its second quarter. ** Vector Group is expected to report quarterly earnings at $0.35 per share on revenue of $337.70 million. ** Aldeyra Therapeutics is estimated to report earnings for its second quarter.

  5. Show article details.

    Preview: Meridian Bioscience's Earnings

    Benzinga – 1:58 PM ET 08/04/2022

    Meridian Bioscience is set to give its latest quarterly earnings report on Friday, 2022-08-05. Analysts estimate that Meridian Bioscience will report an earnings per share of $0.16. Meridian Bioscience bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

  6. Show article details.

    Recap Of Friday's Biotech Catalysts - End of The Day Summary

    Benzinga – 5:24 PM ET 07/29/2022

    Recap Of Friday's Biotech Catalysts - End of The Day Summary

  7. Show article details.

    BRIEF-Meridian Bioscience Receives Re-Authorization From FDA For Its Revogene® Sars-Cov-2 Molecular Assay

    Reuters – 9:27 AM ET 07/29/2022

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE RECEIVES RE-AUTHORIZATION FROM FDA FOR ITS REVOGENE® SARS-COV-2 MOLECULAR ASSAY. * Meridian Bioscience Inc (VIVO) - EXPECTS TO BEGIN SHIPPING THIS PRODUCT BEFORE END OF ITS FISCAL Q4, ENDING SEPTEMBER 30, 2022 Source text for Eikon: Further company coverage:

  8. Show article details.

    Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

    PR Newswire – 9:23 AM ET 07/29/2022

    CINCINNATI, July 29, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration.

  9. Show article details.

    MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

    PR Newswire – 10:10 PM ET 07/27/2022

    NEW ORLEANS, July 27, 2022 Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Meridian Bioscience, Inc. (VIVO) to SD Biosensor, Inc. and SJL Partners LLC.

  10. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

    Benzinga – 10:02 AM ET 07/08/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  11. Show article details.

    MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

    Business Wire – 6:59 PM ET 07/07/2022

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Meridian Bioscience, Inc. (VIVO) to SD Biosensor, Inc. and SJL Partners LLC.

  12. Show article details.

    Meridian Bioscience To Be Acquired By SD Biosensor, SJL Partners - Read For How Much

    Benzinga – 10:45 AM ET 07/07/2022

    Meridian Bioscience To Be Acquired By SD Biosensor, SJL Partners - Read For How Much

  13. Show article details.

    BRIEF-Meridian Says If Deal Is Terminated Under Certain Circumstances, Co Will Be Obligated To Pay To Columbus Holding A Termination Fee $45.96 Million In Cash

    Reuters – 10:38 AM ET 07/07/2022

    Meridian Bioscience Inc (VIVO): * MERIDIAN - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO WILL BE OBLIGATED TO PAY TO COLUMBUS HOLDING A TERMINATION FEE $45.96 MILLION IN CASH Source text - https://bit.ly/3yM5yFU Further company coverage:

  14. Show article details.

    South Korean firms to take Meridian Bioscience private in $1.53 bln deal

    Reuters – 8:19 AM ET 07/07/2022

    Meridian Bioscience Inc (VIVO) will be acquired by SD Biosensor Inc and PE firm SJL Partners LLC in an all-cash $1.53-billion deal, the companies said on Thursday, accelerating the South Korean diagnostic firm's entry into the U.S. market. Meridian shareholders will receive $34 per share in cash, a 1.3% premium to the stock's closing price on Wednesday, under the deal.

  15. Show article details.

    South Korean consortium to buy Meridian Bioscience in $1.53 bln deal

    Reuters – 7:26 AM ET 07/07/2022

    Meridian Bioscience Inc (VIVO) said on Inc and SJL Partners LLC in an all-cash $1.53-billion deal.

  16. Show article details.

    BRIEF-Meridian Bioscience Enters Into Agreement To Be Acquired By SD Biosensor And SJL Partners In $1.53 Bln Deal

    Reuters – 7:20 AM ET 07/07/2022

    SD Biosensor Inc: * MERIDIAN BIOSCIENCE (VIVO), INC. ENTERS INTO AGREEMENT TO BE ACQUIRED BY SD BIOSENSOR AND SJL PARTNERS IN $1.53 BILLION ALL-CASH TRANSACTION. * MERIDIAN BIOSCIENCE INC (VIVO) - SHAREHOLDERS TO RECEIVE $34.00 PER SHARE IN CASH, PROVIDING IMMEDIATE, COMPELLING AND CERTAIN VALUE. * MERIDIAN BIOSCIENCE INC (VIVO) - DEAL FOR APPROXIMATELY $1.53 BILLION.

  17. Show article details.

    BRIEF-Meridian Bioscience Announces Preliminary Results For Fiscal 2022 Third Quarter

    Reuters – 7:18 AM ET 07/07/2022

    Meridian Bioscience Inc (VIVO): * MERIDIAN BIOSCIENCE ANNOUNCES PRELIMINARY RESULTS FOR FISCAL 2022 THIRD QUARTER. * Meridian Bioscience Inc (VIVO) - FOR Q3 OF FISCAL 2022, PRELIMINARY UNAUDITED NET REVENUES ARE EXPECTED TO BE BETWEEN $66 MILLION AND $69 MILLION.

  18. Show article details.

    Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

    PR Newswire – 7:17 AM ET 07/07/2022

    Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biose...

  19. Show article details.

    Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

    PR Newswire – 7:12 AM ET 07/07/2022

    CINCINNATI, July 7, 2022 Meridian Bioscience, Inc. (VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022. For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million.

  20. Show article details.

    Cannabis Stock Gainers And Losers From July 6, 2022

    Benzinga – 5:39 PM ET 07/06/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Aug
    05

    VIVO announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.